Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Heart failure, CV mortality risk higher with aromatase inhibitors vs tamoxifen

25 Feb 2020

Aromatase inhibitors seem to confer heightened risks of heart failure and cardiovascular (CV) mortality when compared with tamoxifen, a study has found.

The study involved 23,525 newly diagnosed breast cancer patients, among whom 17,922 initiated hormonal therapy with either an aromatase inhibitor (n=8,139) or tamoxifen (n=9,783). Anastrozole was the most commonly used aromatase inhibitor (57.7 percent), followed by letrozole (41.7 percent) and exemestane (0.6 percent).

In Cox proportional hazards models with inverse probability of treatment, aromatase inhibitor vs tamoxifen users had an 86-percent increased risk of heart failure (incidence rate, 5.4 vs 1.8 per 1,000 person-years; hazard ratio [HR], 1.86, 95 percent confidence interval [CI], 1.14–3.03) and 50-percent higher risk of CV mortality (incidence rate, 9.5 vs 4.7 per 1,000 person-years; HR, 1.50, 95 percent CI, 1.11–2.04).

Aromatase inhibitors were also associated with a trend toward heightened risks of myocardial infarction (incidence rate, 3.9 vs 1.8 per 1,000 person-years; HR, 1.37, 95 percent CI, 0.88–2.13) and ischaemic stroke (incidence rate, 5.6 vs 3.2 per 1,000 person-years; HR, 1.19, 95 percent CI, 0.82–1.72). The estimates were robust to several sensitivity analyses.

The higher risk of CV events associated with aromatase inhibitors should be balanced with their favourable clinical benefits relative to tamoxifen, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.